The effect of meloxicam and cryopreserved placenta extract on initial inflammatory response - an experimental study

Area of Science:

• Pharmacology
• Inflammation Research
• Tissue Repair

Background:

• The initial phase of inflammation, known as alteration, is critical for inflammatory cascade progression and tissue damage.
• Early suppression of inflammation is vital for effective anti-inflammatory therapies.
• Combining nonsteroidal anti-inflammatory drugs with agents possessing pleiotropic mechanisms may enhance anti-inflammatory efficacy.

Purpose of the Study:

• To evaluate the combined effect of cryopreserved placenta extract and meloxicam on the alterative phase of inflammation.
• To assess the efficacy of this combination in a rat model of aseptic skin and subcutaneous tissue inflammation.

Main Methods:

• Induction of aseptic skin and subcutaneous tissue inflammation in rats using subcutaneous acetic acid and dextran.
• Administration of meloxicam, cryopreserved placenta extract, or their combination.
• Measurement of necrotic ulcer area as a primary outcome indicator at day 7 and day 27.

Main Results:

• Acetic acid and dextran induced necrotic ulcers in 100% of rats by day 7.
• Combined meloxicam and placenta extract demonstrated the most significant antialterative effect (23.9%) on day 7, reducing ulcer area by 1.3-fold (p < 0.05) compared to controls.
• On day 27, the combined treatment showed a 1.7-fold greater antialterative effect than meloxicam monotherapy and a 1.2-fold greater effect than placenta extract monotherapy.

Conclusions:

• Combined administration of meloxicam and cryopreserved placenta extract exhibits a potent antialterative effect on inflammation.
• This combination therapy surpasses the efficacy of monotherapy with either meloxicam or placenta extract in reducing inflammatory tissue damage.
• The findings suggest a synergistic or additive benefit of combining these agents for managing the early stages of inflammation.